Narcolepsy Type News Today

TAK-861 demonstrated significant and sustained improvements in the treatment of narcolepsy type 1 in a phase 2b clinical trial.

- Late-Breaking Abstracts Containing Data From the Full Narcolepsy Type 1 Cohort From the ALKS 2680 Phase 1b Study and Vibrance-1 Phase 2 Study Design Accepted for Poster Presentations - -

ALKS 2680 reports positive results in narcolepsy & idiopathic hypersomnia study. Statistically significant improvements in sleep latency were observed across all doses tested. Phase 2 study for NT2 patients is planned for 2nd half of 2024. Jefferies raises price target & probability of success for ALKS-2680.

Here are some updates from the world of psychiatry throughout the month of February.

Essen Bakery owner Tova du Plessis recently took to social media to document her struggle and recent diagnosis of Narcolepsy Type 1. She has been struggling with the rare disease for 14 months, and according to her, that time has been “debilitating”, making it difficult to run the bakery and oversee the brand’s expansion to […]

In this article, we will be taking a look at the 20 fastest growing biotech companies in the US. If you are not interested in learning about the landscape of biotech companies, head straight to the 5 Fastest Growing Biotech Companies In The US. The biotechnology sector in the United States is witnessing a surge […]

In a decade, Christophe Weber remade Takeda into a global pharma leader, shifting from a fragmented structure to a unified innovator.

Takeda TSE4502NYSETAK today announced positive topline results from a randomized doubleblind placebocontrolled multiple dose Phase 2b trial evaluating TAK861 an oral orexin receptor 2 OX2R agonist in patients with narcolepsy type 1.

− Primary and Key Secondary Endpoints Were Met in Narcolepsy Type 1 Phase 2b Trial− TAK-861 Was Found to be Generally Safe and Well-Tolerated− Results Will be Presented at an Upcoming Scientific CongressOSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced positive topline resu...

October 25, 2023 Alkermes Q3 2023 Earnings Conference Call Prepared Remarks Sandy Coombs: Welcome to the Alkermes plc...